Streamlining mRNA Production

November 8, 2023 / by Nate Spangler, Ph.D.

Seeking guidance for a big investment

Messenger RNA (mRNA) based drugs and vaccines make up a new class of medicine showing tremendous promise. Compared to established drug and vaccine technologies, mRNA has the potential to reach patients faster by being easier to develop and produce.

But that’s not to say that the production of mRNA-based medicines is simple; it involves many steps requiring a range of specialized expertise and capabilities. This is where contract development and manufacturing organizations (CDMOs) can be beneficial. Outsourcing is an effective way to access specialized capabilities, adaptable experience, and honed expertise for getting drug products to the market faster.

In an ongoing series of blog posts, we will explore key factors to consider when evaluating CDMO options, with an emphasis on streamlining and de-risking supply chains by finding a CDMO that can satisfy as many needs as possible from a single supplier. Topics we will consider include:

• Pros and cons of relying on multiple outsourcing partners
• Advantages of comprehensive capabilities from a single partner
• Criteria for finding the right CDMO

Much of this series will be on the last point where expertise, capabilities, reputation, and flexibility come into focus. Finding the right CDMO involves many considerations. The goal of this series of posts is to provide an overview to help those developing mRNA-based medicines choose outsourcing partners wisely.

• Have questions about this topic? Contact Nate Spangler
• Learn more about Aldevron's mRNA capabilities
• Have an idea for a topic? Let us know!